Sponsors
We would like to thank our sponsors for their support and financial contributions towards the conference. Sponsors have had no input into the arrangements for the conference including the agenda, content and speakers (apart from sponsored and satellite symposia).
Online Series Partner: Sanofi
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
For more information please visit www.sanofi.co.uk.
Adverse events should be reported. Reporting forms and information can be found at www.Mhra.Gov.Uk/Yellowcard . Adverse events should also be reported to Sanofi Tel: 0800 0902314. Alternatively, send via email to uk drugsafety@sanofi.com
MAT-GB-2003339 (V1.0) DoP Oct 2020
| Date | Time | Sponsored Symposia Description |
| Wednesday 28 October | 19:00-20:00 |
Diabetes management: Why doing nothing is not an option Speakers: MAT-GB-2002970 (V1.0) DoP Oct 2020 |
Please note this session is not eligible for accreditation
Premium Sponsor: Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 with a heritage that has given us experience and capabilities that enable us to help people defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders.
Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 80 countries and markets its products in around 170 countries. Every day, millions of people all over the world rely on our products, which are manufactured in seven countries.
Novo Nordisk has a unique ownership structure, with two-thirds of Novo
Nordisk’s shares controlled by the Novo Nordisk Foundation. The objective of the Foundation is to provide a stable basis for the commercial and research activities of Novo Nordisk and support scientific, humanitarian and social purposes.
We work to prevent, treat and ultimately cure disease by pioneering scientific breakthroughs and expanding access to our medicines. Novo Nordisk also holds leading positions in the management of bleeding disorders, growth hormone treatment and hormone replacement therapy.
For more information visit novonordisk.co.uk
| Date | Time | Sponsored symposia description |
| Wednesday 18 November | 19:00-20:00 |
Rybelsus®▼ (semaglutide tablets) in clinical practice This symposium is for UK HCPs only and has been organised and funded by Novo Nordisk. Prescribing information and adverse event reporting information is available at the session. Speakers: Dr Sarah Davies, GP Partner – Woodlands Medical Centre, Cardiff Dr Samuel Seidu, GP Partner – Hockley Farm Medical Practice, Leicester |
Please note this session is not eligible for accreditation
